We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,653.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European shares suffer as trade jitters, weak data weigh

Thu, 22nd Mar 2018 17:40

* STOXX 600 down 1.6 pct to 2-week low

* Banks, miners, tech lead sectoral fallers

* Reckitt gains after pulling out of Pfizer race(Adds details, closing prices)

By Helen Reid and Danilo Masoni

LONDON, March 22 (Reuters) - Concerns about trade sentEuropean shares tumbling on Thursday as the United Statesprepared to announce hefty tariffs on Chinese imports, withbanks, basic resources stocks and tech the worst-performing.

U.S. President Donald Trump signed a presidential memorandumthat could impose tariffs on up to $60 billion in Chineseimports.

Separately, the European Union secured an exemption fromU.S. tariffs on steel and aluminium imports set to come intoforce on Friday.

The pan-European STOXX 600 index fell 1.6 percentto its lowest level in more than two weeks, while Germany'sexporter- and industrials-heavy DAX fell 1.7 percent.

The mood was also dampened by a weaker than forecastbusiness activity survey. Euro zone businesses rounded off thefirst quarter of 2018 with their slowest growth in over a year,much weaker than expected, as new business took another hit froma stubbornly strong euro.

"Business sentiment has to be monitored carefully in thecoming months, especially if trade tensions intensify, becauseany further significant deterioration in confidence indicatorsmight signal that the balance of risks starts shifting to thedownside," said UniCredit head of macro research Marco Valli.

Banks, which have been penalized recently weaker thanexpected macro economic data in Europe, were among the leadinglosers on Thursday. Their sectoral index fell 2.5percent to an 11-month low. The sector also suffered after theU.S. Federal Reserve surprised the market with less hawkish rateguidance.

Deutsche Bank declined 2.9 percent, still weakafter sharp losses in the previous session when the bank'sfinance chief said a strong euro and higher funding costs wouldhave a 450 million euro impact on revenues.

Commerzbank tumbled 6.2 percent after a downgradefrom Kepler Cheuvreux.

Basic resources stocks led sectoral losers, down 2.9percent after copper reversed earlier gains to fall tothree-month lows as escalating concern about U.S. plans to levyduties on Chinese imports.

Tech stocks < .SX8P> 2.1 as tariffs on China were expectedto target the high-tech sector.

Chipmakers ams, STMicro, and Infineon, which have led the recent tech stock rally and arefirmly embedded in international supply chains, all fell. .

Deal developments and earnings continued to drive Europeanstock moves.

Reckitt Benckiser shares shone, jumping 4.8 percentafter the British consumer products firm pulled out of thebidding for Pfizer's consumer health unit.

The move reflected relief in the market that Reckitt wouldavoid over-levering or issuing shares for the acquisition.

GlaxoSmithKline, now seen as having a better chanceof buying the Pfizer business, declined 1.7 percent.

Disappointing 2017 results sent United Internetshares down 9.5 percent. Subsidiary Drillisch fell 5.7percent.

Also in tech, Ingenico suffered a 3.4 percent lossafter Kepler Cheuvreux downgraded it, saying full-year guidancenow looked "challenging".

Tech and engineering consultancy Altran fell 3.3percent after launching a share capital increase of 750 millioneuros.

The world’s no.2 cement maker Heidelberg Cementfell 2.3 percent after it announced a dividend slightly short ofanalysts’ average expectations.

Bayer fell 1.4 percent after Australian and EUregulators approved the firm's takeover of Monsanto. "Halfwaythere," wrote UBS analysts, adding all eyes were now on the U.S.Department of Justice, yet to approve the deal.

Overall, with results season drawing to a close, analystswere becoming more negative on the earnings outlook for Europeanstocks.

(Reporting by Helen Reid and Danilo Masoni, Editing by RichardBalmforth and Hugh Lawson)

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.